HoloSIM: Mixed Reality Medical Student Training in Complex Crisis Scenarios (HoloSIM)
HoloSIM: The Way Forward in Complex Crisis Training
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Julian Wiegelmann
- Phone Number: 4164804864
- Email: julian.wiegelmann@sunnybrook.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4E 3M4
- Recruiting
- Sunnybrook Health Sciences Centre
-
Contact:
- Julian R Wiegelmann, MD
- Phone Number: 416-480-4864
- Email: julian.wiegelmann@sunnybrook.ca
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- University of Toronto Medical student volunteers
Exclusion Criteria:
- Unwilling to enter the study
- Deficit of vision or hearing incompatible with Microsoft Hololens 2 use
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Training by Mixed Reality Simulation
|
Medical students will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2
|
|
ACTIVE_COMPARATOR: Training by Mannequin Based Simulation
|
Medical students will train a via traditional mannequin based medical crisis scenario
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anaphylaxis Checklist of Core Decision Making Steps
Time Frame: one week post exposure
|
Expert consensus based checklists of critical scenario actions on a mannequin based crisis scenario.
Student scenario performance graded from 0 to 45, with higher scores representing a better performance.
|
one week post exposure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Usability Score
Time Frame: Immediately after exposure
|
Likert scale (5 point) based assessment of software usability.
Higher scores on a scale of 1 to 5 represent a better software system usability.
|
Immediately after exposure
|
|
Learning Satisfaction Score
Time Frame: Immediately after exposure
|
Likert scale (5 point) based assessment of learning satisfaction.
Higher scores on a scale of 1 to 5 represent a greater degree of learning satisfaction.
|
Immediately after exposure
|
|
Time required to complete critical crisis related tasks
Time Frame: one week post exposure
|
Measured time until critical scenario management events occur
|
one week post exposure
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- SUN-2124
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.